Optinose Announces Pricing of Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- US stock futures rise after previous session's selloff
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Optinose (OPTN) PT Lowered to $9 at BMO Capital
November 17, 2021 9:08 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Optinose (NASDAQ: OPTN) to $9.00 (from $16.00) while maintaining an Outperform rating.
The analyst commented, "3Q Xhance revenue was slightly below and 2021 guidance lowered given continued COVID-19 headwinds impacting sales access and Rx volumes (though... More
